# Xilio Therapeutics Inc. COM

Xilio Therapeutics Inc. COM is a security (CUSIP 98422T100) tracked across SEC portfolio filings. 4 institutional managers reported $8.3M on Form 13F as of 2026-06-30.

## Summary

- Issuer: Xilio Therapeutics Inc.
- Class: COM
- CUSIP: 98422T100
- 13F holders: 4
- 13F value: $8.3M
- 13F period: 2026-06-30
- N-PORT fund positions: 0

## Top institutional holders (Form 13F)

| Manager | Location | Value | Shares |
| --- | --- | --- | --- |
| GILEAD SCIENCES, INC. | FOSTER CITY, CA | $6.2M | 650,389 |
| TAKEDA PHARMACEUTICAL CO LTD | Tokyo, M0 | $1.2M | 1,475,121 |
| [VANGUARD GROUP INC](https://search.stillhousedata.com/firm/105958) | Valley Forge, PA | $804K | 1,255,692 |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | BIRMINGHAM, AL | — | 0 |

## More

- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/security/98422T100.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.